부산대학교 도서관

Summary:The authors review new therapeutic approaches for Croh's disease, based on biological agents counteracting Immunological and inflammatory mechanisms activated in the inflamed mucosa. The most studied drug is infliximab, which has been demonstrated extremely effective in thioprine, 6-mercaptopurine) or methotrexate. The impact of infliximab on health economics is favourable: reduction of admissions, etc. Potential adverse reactions to infliximab are reviewed. A long term pharmacovigilance is necessary. Other anti-TNFalpha therapies are reviewed, as well as promising non anti-TNFalpha biological therapies which are currently evaluated by many clinical trials.